GAD65 (B96) Human Monoclonal [AB-N13]

Antibodies to glutamic acid decarboxylase-65 (GAD65) are present in autoimmune disorders such as insulin-dependent (type1) diabetes mellitus (IDDM), stiff man syndrome, and polyendocrine autoimmune disease. Autoantibodies to GAD65 are present in 60-70% of individuals with newly diagnosed IDDM, and thus are important markers for disease activity. These autoantibodies usually recognize conformation-dependent regions on GAD65 and rarely bind to the second isoform, GAD67. Autoantibodies to GAD67 are found in only 15% of recent-onset IDDM patients, and most of this binding can be blocked with GAD65, suggesting shared epitopes between the two isoforms of GAD.

This antibody is specific for the 65-kDa isoform of glutamic acid decarboxylase (GAD65), targeting the IDDM-E2 region (amino acids 451-570), and does not bind GAD67. To create this cell line, peripheral blood B-cells were obtained from a donor who tested positive for GAD65 autoantibodies and were immortalized with Epstein-Barr virus.

Applications include immunoprecipitation, immunohistochemistry, and protein footprinting. This antibody does not work in Western blotting.

GAD65 Products:

GAD65 (B78) Human Monoclonal (Cat. #AB-N12) | biotin-labeled (Cat. #AB-N12-BT) | Alexa488-labeled (Cat. #AB-N12-FLA)

GAD65 (B96) Human Monoclonal (Cat. #AB-N13) | biotin-labeled (Cat. #AB-N13-BT) | Alexa488-labeled (Cat. #AB-N13-FLA)

keywords: glutamic acid decarboxylase, gad, gad 65, GAD65, Anti-GAD65, Anti-Glutamic Acid Decarboxylase-65